GORDON CARL L

Director Carl L. Gordon sells entire 3,571,428 share position (100% exit) at $1.59, company shows $0.00 revenue and $-10,481,000 net income

Carl L. Gordon, a Director at Compass Therapeutics, liquidated his complete shareholding of 3,571,428 shares for $5,678,570.52 on 2025-04-09 at $1.59 per share, leaving zero shares post-transaction. The complete exit is notable against the company's operational backdrop: latest quarter revenues are $0.00, and the company posted a net loss of $-10,481,000 over its most recent full fiscal year. The stock has declined 56.4% from its 52-week high of $3.90 and 32.3% over the past 30 days alone. While Gordon's cross-ticker track record shows 2 prior open-market sells with an average 90-day post-sale return of +54.8% (indicating poorly-timed historical sells when his exits preceded subsequent rallies), this particular transaction occurs in a context of accelerating price deterioration and ongoing unprofitability with no revenue generation.

Director Carl L Gordon bought 190,672 shares in 4 transactions for $2,020,755.60 (blended avg $10.60)

Director Carl L Gordon made 4 separate purchases of MBX Biosciences stock totaling 190,672 shares for $2,020,755.60, increasing his holdings by 34.2% from 557,215 to 747,887 shares. The purchases spanned February 14–18, 2025, at prices ranging from $9.85 to $10.84, while the current price stands at $11.22—a position 56.8% below the 52-week high of $25.98. Gordon's cross-ticker buy track record shows 18 prior open-market purchases with an average 90-day return of +192.5% and a 61.11% win rate, and his prior two transactions at MBX (both in September 2024) each returned +18.4% over 90 days. Notably, the company is currently unprofitable with net income of $-18,142,000.00, making this a substantial capital commitment into a loss-making enterprise during a period when the stock trades significantly below recent highs.

Director GORDON CARL L buys 750,000 shares for $12,000,000 at MBX; 14 other insiders also bought in past 14 days

Director GORDON CARL L executed 2 separate purchases totaling 750,000 shares for $12,000,000.00 at $16.00 per share on 2024-09-16, converting derivative securities into common equity. This purchase occurred during a cluster period in which 14 other insiders also made acquisitions within the past 14 days, suggesting coordinated capital commitment across the insider group. The current price of $21.50 as of 2024-09-17 represents a $5.50 premium to the transaction price, though the stock is recently listed (3 trading days) and 52-week benchmarks are not yet meaningful. The concentrated buying activity across multiple insiders during this early trading period warrants monitoring to understand the drivers behind the coordinated capital deployment.

Director GORDON CARL L sold 250,000 shares at $44.01 for $11.0M, reducing stake by -67.7% to 119.5K shares

Director Carl L. Gordon executed 2 separate sales totaling 250,000 shares for $11,002,500.00 at $44.01 per share on 2024-08-13, divesting 67.7% of his pre-transaction holdings. The sale occurs as the stock trades at $46.04 (current price), -34.7% from its 52-week high of $70.48 and down 11.8% over the past 30 days. Keros Therapeutics reported revenue of $37,000.00 in the latest quarter and net income of -$45,257,000.00 with persistent unprofitability, creating a fundamental backdrop of cash burn and commercial challenges. Gordon's cross-ticker track record shows positive historical timing with 65% win rate on his prior 20 open-market buys (avg 90d return +173.7%), but this metric does not apply to his sale behavior at this ticker and carries no predictive weight for the direction of KROS post-sale.